{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:09:59Z","timestamp":1765814999787,"version":"3.48.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":330,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2023YFC2706301"],"award-info":[{"award-number":["2023YFC2706301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800789"],"award-info":[{"award-number":["81800789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873661"],"award-info":[{"award-number":["81873661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>5q-spinal muscular atrophy (SMA) is a fatal autosomal recessive disease characterized by the progressive muscle weakness and atrophy. In this retrospective study, we described the long-term clinical outcomes of novel disease-modifying therapies (DMTs) for 5q-spinal muscular atrophy, drawing on experience from southern China. This is a single-centre large cohort which enrolled 102 paediatric patients confirmed with 5q-spinal muscular atrophy at Guangzhou Women and Children\u2019s Medical Center from 2019 to 2024. One hundred and two patients were included, 24 were classified as SMA type 1, 56 with type 2 and 22 with type 3. One hundred per cent of the patients received nusinersen, with 31 (30.3%) patients starting risdiplam and 2 patients transitioning to zolgensma therapy. Over the 5-year treatment and follow-up period (2019\u201324), the survival rate reached 97.08%. One child with SMA type 1 and two with SMA type 2 died while receiving nusinersen monotherapy. Compared with baseline, the enrolled SMA patients exhibited statistically significant motor function gains. Nevertheless, type 1 patients experienced weight loss, while linear growth was compromised in both type 1 and type 2 patients after treatment. Serum insulin-like growth factor-1 levels rose modestly in types 1 and 2, but the increase did not reach statistical significance. Respiratory tract infections, malnutrition, scoliosis and fracture are the main complications and potential life-threatening risk factors during DMTs. Moreover, longer diagnostic to treatment intervals were significantly and inversely associated with motor function gains and directly associated with higher complication rates. This retrospective study confirms the effectiveness of nusinersen and risdiplam for 5q-spinal muscular atrophy and highlights the critical importance of early initiation of DMTs.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf453","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:03:41Z","timestamp":1764162221000},"source":"Crossref","is-referenced-by-count":0,"title":["Five-year disease-modifying therapeutic experience of 102 Chinese paediatric 5q-spinal muscular atrophy: a retrospective analysis"],"prefix":"10.1093","volume":"7","author":[{"given":"Minyan","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuili","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Paediatric Neurology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaishou","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Paediatric Physiotherapy, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Paediatric Physiotherapy, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Paediatric Intensive Care Unit, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruidan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neonatal, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Genetic Metabolism, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University , Guangzhou 510623 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"4","key":"2025121511070583900_fcaf453-B1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"2025121511070583900_fcaf453-B2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - A literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"volume-title":"Genereviews","year":"1993\u20132025","author":"Prior","key":"2025121511070583900_fcaf453-B3"},{"key":"2025121511070583900_fcaf453-B4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Participants of the international conference on SMA standard of care. Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"2025121511070583900_fcaf453-B5","doi-asserted-by":"crossref","first-page":"1294028","DOI":"10.3389\/fneur.2023.1294028","article-title":"Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: Findings from a three-year nationwide study in Korea","volume":"14","author":"Cho","year":"2023","journal-title":"Front Neurol"},{"issue":"4","key":"2025121511070583900_fcaf453-B6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: A review in spinal muscular atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"issue":"3","key":"2025121511070583900_fcaf453-B7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): Test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"2025121511070583900_fcaf453-B8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol"},{"issue":"9","key":"2025121511070583900_fcaf453-B9","doi-asserted-by":"crossref","first-page":"e0238786","DOI":"10.1371\/journal.pone.0238786","article-title":"Assessment of the validity and reliability of the 32-item motor function measure in individuals with type 2 or non-ambulant type 3 spinal muscular atrophy","volume":"15","author":"Trundell","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"2025121511070583900_fcaf453-B10","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: A 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun"},{"issue":"7","key":"2025121511070583900_fcaf453-B11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eprac.2022.04.004","article-title":"Pediatric continuous reference intervals of serum insulin-like growth factor 1 levels in a healthy Chinese children population - Based on PRINCE study","volume":"28","author":"Cao","year":"2022","journal-title":"Endocr Pract"},{"key":"2025121511070583900_fcaf453-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"18","key":"2025121511070583900_fcaf453-B13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121511070583900_fcaf453-B14","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1007\/s00415-024-12442-w","article-title":"Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: A multi-center disease registry in China","volume":"271","author":"Yao","year":"2024","journal-title":"J Neurol"},{"issue":"10","key":"2025121511070583900_fcaf453-B15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/healthcare11101515","article-title":"Real world evidence on the effectiveness of nusinersen within the national program to treat spinal muscular atrophy in Poland","volume":"11","author":"Krupa","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"2025121511070583900_fcaf453-B16","doi-asserted-by":"crossref","first-page":"e200374","DOI":"10.1212\/CPJ.0000000000200374","article-title":"Spinal muscular atrophy update in best practices: Recommendations for treatment considerations","volume":"15","author":"Schroth","year":"2025","journal-title":"Neurol Clin Pract"},{"key":"2025121511070583900_fcaf453-B17","first-page":"54","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single-centre Australian experience","volume":"39","author":"Chen","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"2025121511070583900_fcaf453-B18","doi-asserted-by":"crossref","first-page":"1152318","DOI":"10.3389\/fped.2023.1152318","article-title":"Adverse events in the treatment of spinal muscular atrophy in children and adolescents with nusinersen: A systematic review and meta-analysis","volume":"11","author":"Zhong","year":"2023","journal-title":"Front Pediatr"},{"issue":"1","key":"2025121511070583900_fcaf453-B19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13023-021-02015-9","article-title":"Growth patterns in children with spinal muscular atrophy","volume":"16","author":"De Amicis","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2025121511070583900_fcaf453-B20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/nutrit\/nuz109","article-title":"Nutritional practices in pediatric patients with neuromuscular disorders","volume":"78","author":"Chou","year":"2020","journal-title":"Nutr Rev"},{"issue":"4","key":"2025121511070583900_fcaf453-B21","first-page":"495","article-title":"A theoretical link between the GH\/IGF-1 axis and cytokine family in children: Current knowledge and future perspectives","volume":"12","author":"Cammisa","year":"2025","journal-title":"Children (Basel)"},{"issue":"3","key":"2025121511070583900_fcaf453-B22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5603\/PJNNS.a2021.0020","article-title":"Nusinersen treatment of spinal muscular atrophy type 1- Results of expanded access programme in Poland","volume":"55","author":"Modrzejewska","year":"2021","journal-title":"Neurol Neurochir Pol"},{"issue":"7","key":"2025121511070583900_fcaf453-B23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: Final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"2025121511070583900_fcaf453-B24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf453\/65552357\/fcaf453.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/6\/fcaf453\/65552357\/fcaf453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/6\/fcaf453\/65552357\/fcaf453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:07:14Z","timestamp":1765814834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf453\/8343588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf453","relation":{},"ISSN":["2632-1297"],"issn-type":[{"type":"electronic","value":"2632-1297"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf453"}}